Growth differentiation factor 15: A novel biomarker with high clinical potential

Desmedt, Stéphanie; Desmedt, Valérie; Vos, Leen De; Delanghe, Joris; Speeckaert, Reinhart; Speeckaert, Marijn M.

doi:10.1080/10408363.2019.1615034

Cited by 78 publications

(64 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among 14,577 patients with stable CAD participating in the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY), GDF15 was found to be independently associated with CV, non-CV, and cancer mortality. Furthermore, GDF15 concentrations were lowest in patients with NGT, intermediate in patients with prediabetes, and highest in patients with T2D (26). Strengthening this finding, the Malmö Diet and Cancer-Cardiovascular Cohort, in which 4,360 participants with normoglycemia were followed for 19 years, recently showed that GDF15 may be useful for the identification of people with a risk of incident diabetes (27).…”

Section: Discussionmentioning

confidence: 88%

Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study

et al. 2020

View full text Add to dashboard Cite

Coronary artery disease (CAD) is a major challenge in patients with type 2 diabetes (T2D). Coronary computed tomography angiography (CCTA) provides a detailed anatomic map of the coronary circulation. Proteomics are increasingly used to improve diagnostic and therapeutic algorithms. We hypothesized that the protein panel is differentially associated with T2D and CAD. RESEARCH DESIGN AND METHODSIn CAPIRE (Coronary Atherosclerosis in Outlier Subjects: Protective and Novel Individual Risk Factors Evaluationda cohort of 528 individuals with no previous cardiovascular event undergoing CCTA), participants were grouped into CAD 2 (clean coronaries) and CAD 1 (diffuse lumen narrowing or plaques). Plasma proteins were screened by aptamer analysis. Two-way partial least squares was used to simultaneously rank proteins by diabetes status and CAD. RESULTSThough CAD 1 was more prevalent among participants with T2D (HbA 1c 6.7 6 1.1%) than those without diabetes (56 vs. 30%, P < 0.0001), CCTA-based atherosclerosis burden did not differ. Of the 20 top-ranking proteins, 15 were associated with both T2D and CAD, and 3 (osteomodulin, cartilage intermediate-layer protein 2, and HTRA1) were selectively associated with T2D only and 2 (epidermal growth factor receptor and contactin-1) with CAD only. Elevated renin and GDF15, and lower adiponectin, were independently associated with both T2D and CAD. In multivariate analysis adjusting for the Framingham risk panel, patients with T2D were "protected" from CAD if female (P 5 0.007), younger (P 5 0.021), and with lower renin levels (P 5 0.02). CONCLUSIONSWe concluded that 1) CAD severity and quality do not differ between participants with T2D and without diabetes; 2) renin, GDF15, and adiponectin are shared markers by T2D and CAD; 3) several proteins are specifically associated with T2D or CAD; and 4) in T2D, lower renin levels may protect against CAD.Cardiovascular (CV) disease has steadily represented the leading cause of death in the world for the past 15 years, with coronary artery disease (CAD) and stroke being responsible for a combined 15 million deaths in 2016 (1). Morbidity and mortality of patients with CAD is considerably higher in the presence of diabetes, accounting for ;50% of deaths in this population (2). Therefore, detection of CAD and its risk factors

show abstract

Section: Discussionmentioning

confidence: 88%

Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…18 However, GDF-15 studies are conducted in other diseases such as diabetic complications, inflammatory conditions and tumors. 19,20 Few studies have described the association of GDF-15 levels with progression of kidney dysfunction. A Study of Nair et al 21 found that the intrarenal expression of GDF15 in the tubulointerstitial cavity of CKD patients is reflected in the serum levels of GDF-15, these are significantly correlated with the progression of the disease, as described by a continuous decrease in eGFR or a cumulative endpoint of 30% in eGFR or progression to ESRD, irrespective of many risk factors for kidney disease progression.…”

Section: Gdf-15 Is a Risk Factor In Ckd Patients With Diabetic Nephromentioning

confidence: 99%

GDF-15 A potential Biomarker of Diabetic Nephropathy in Iraq Patients with Chronic Kidney Disease

2021

TJNPR

View full text Add to dashboard Cite

“…However, until now there is no "gold standard" for ICU-AW assessment and diagnosis [5], and especially there is a lack of certain biomarkers with high diagnostic value. Growth differentiation factor-15 (GDF-15) is a transforming growth factor β (TGF-β) protein that has been shown to be involved in the development of muscle atrophy in a variety of diseases, including chronic obstructive pulmonary disease (COPD), cancer, and pulmonary hypertension, and is associated with skeletal muscle wasting [6][7][8]. e present study is an observational research.…”

Section: Introductionmentioning

confidence: 96%

Utility of Plasma GDF‐15 for Diagnosis and Prognosis Assessment of ICU‐Acquired Weakness in Mechanically Ventilated Patients: Prospective Observational Study

Xie

Liu

Zheng

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objective. To identify the clinical correlations between plasma growth differentiation factor-15 (GDF-15), skeletal muscle function, and acute muscle wasting in ICU patients with mechanical ventilation. In addition, to investigate its diagnostic value for ICU-acquired weakness (ICU-AW) and its predictive value for 90-day survival in mechanically ventilated patients. Methods. 95 patients with acute respiratory failure, who required mechanical ventilation therapy, were randomly selected among hospitalized patients from June 2017 to January 2019. The plasma GDF-15 level was detected by ELISA, the rectus femoris cross-sectional area (RFcsa) was measured by ultrasound, and the patient’s muscle strength was assessed using the British Medical Research Council (MRC) muscle strength score on day 1, day 4, and day 7. Patients were divided into an ICU-AW group and a non-ICU-AW group according to their MRC-score on the 7th day. The differences in plasma GDF-15 level, MRC-score, and RFcsa between the two groups were compared on the 1st, 4th, and 7th day after being admitted to the ICU. Then, the correlations between plasma GDF-15 level, RFcsa loss, and MRC-score on day 7 were investigated. The receiver operating characteristic curve (ROC) was used to analyze the plasma GDF-15 level, RFcsa loss, and % decrease in RFcsa on the 7th day to the diagnosis of ICU-AW in mechanically ventilated patients. Moreover, the predictive value of GDF-15 on the 90-day survival status of patients was assessed using patient survival curves. Results. Based on whether the 7th day MRC-score was <48, 50 cases were included in the ICU-AW group and 45 cases in the non-ICU-AW group. The length of mechanical ventilation, ICU length of stay, and hospital length of stay were significantly longer in the ICU-AW group than in the non-ICU-AW group (all P<0.05), while the other baseline indicators were not statistically significant between the two groups. As the treatment time increased, the plasma GDF-15 level was significantly increased, the ICU-AW group demonstrated a significant decreasing trend in the MRC-score and RFcsa, while no significant changes were found in the non-ICU-AW group. In the ICU-AW group, the plasma GDF-15 level was significantly higher than that in the non-ICU-AW group, while the RFcsa and the MRC-score were significantly lower than those in the non-ICU-AW group (GDF-15 (pg/ml): 2542.44 ± 629.38 vs. 1542.86 ± 502.86; RFcsa (cm2): 2.04 ± 0.64 vs. 2.34 ± 0.61; MRC-score: 41.22 ± 3.42 vs. 51.42 ± 2.72, all P<0.001). The plasma GDF-15 level was significantly negatively correlated with the MRC-score (r = −0.60), while it was significantly positively correlated with the RFcsa loss (r = 0.18) and the % decrease in RFcsa (r = 0.16). Moreover, the RFcsa loss was significantly negatively correlated with the MRC-score (r = −0.27) (all P<0.001). The ROC curve analysis showed that plasma GDF-15 level, RFcsa loss, and % decrease in RFcsa on day 7 had predictive value for ICU-AW diagnosis in mechanically ventilated patients. More specifically, the area under the ROC curve (AUC) of GDF-15 was 0.904, the AUC of RFcsa loss was 0.873, and the AUC of % decrease in RFcsa was 0.886 (all P<0.001). The 90-day survival curve demonstrated that the survival rate of the high plasma GDF-15 level group was 54.00%, while that of the low plasma GDF-15 level group was 75.56%. The difference between the two groups was statistically significant (P<0.05). Conclusion. The plasma GDF-15 concentration level was significantly associated with skeletal muscle function and muscle wasting on day 7 in ICU patients with mechanical ventilation. Therefore, it can be concluded that the plasma GDF-15 level on the 7th day has a high diagnostic yield for ICU-acquired muscle weakness, and it can predict the 90-day survival status of ICU mechanically ventilated patients.

show abstract

Growth differentiation factor 15: A novel biomarker with high clinical potential

Cited by 78 publications

References 161 publications

Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study

Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study

GDF-15 A potential Biomarker of Diabetic Nephropathy in Iraq Patients with Chronic Kidney Disease

Utility of Plasma GDF‐15 for Diagnosis and Prognosis Assessment of ICU‐Acquired Weakness in Mechanically Ventilated Patients: Prospective Observational Study

Contact Info

Product

Resources

About